close

Labopharm Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies. It offers once-daily formulation of the analgesic tramadol under the RYZOLT brand name for the treatment of severe chronic pain in adults. The company sells RYZOLT primarily in the United States, Europe, Canada, South Korea, and Australia. Labopharm's products in pipeline include once-daily formulation of trazodone, a serotonin antagonist reuptake inhibitor for the treatment of depressive disorder. Its product candidates in clinical development based on Contramid platform comprise twice-daily formulation of tramadol plus acetaminophen to address acute pain; and Abuse Deterrent Platform to provide safer medications through resistance to the uncontrolled release of the active ingredient after actions, such as breaking, chewing, crushing and heating, or consumption with alcohol. Its product candidates in clinical development based on the Polymeric Nano-Delivery System platform comprise lipid-and preservative-free formulation of the intravenous anaesthetic agent propofol; and SN-38, which is the active metabolite in the prescribed intravenous colon cancer drug irinotecan. Labopharm was formerly known as Centre de recherche appliquee pharmaceutique CRAP inc. and changed its name to Labopharm Inc. in September 1994. The company was founded in 1990 and is headquartered in Laval, Canada.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	9999.99
Volume	245222
Volume Avg	(mio) 1068.04
52 Week High	0.27
52 Week Low	-0.48
PE	N/A
PE (group average)	N/A
EPS Year	0.00
EPS change Q/Q	0%
EPS change Q/Q Yr ago	-8.33%
EPS change Q/Q next Q est	1000%
EPS change Y/Y	-8.89%
REV change Q/Q	-12.87%
REV change Q/Q Yr ago	23.94%
EPS next Q est	0.20
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%